Protocol summary

Study aim
Investigation of the effects of vaginal probiotic capsules on prolonging the time of membrane rupture up to delivery and on maternal and fetal complications
Design
In this study, 64 pregnant women who have the inclusion criteria and refer to Ghaem, Emam Reza and Ommolbanin hospitals are chosen. Participants are randomly divided to intervention and control group (Randomization is done by computer).
Settings and conduct
Regarding that the most important factor in neonatal death is Preterm delivery, and on the other hand the reason of 35 percent of these Preterm delivery is preterm membrane rupture and also due to the fact that after delivery, the more the age, the less the complications related to preterm infant, in this study. Therefore, with the prescription of vaginal probiotic capsules and maintaining normal vaginal microbial flora, it is aimed to increase pregnancy age and reduce the complications of being preterm. This study will be carried out in Ghaem, Emam Reza and Ommolbanin hospitals in Mashhad. No blinding is done and patients are randomly divided to two groups.
Participants/Inclusion and exclusion criteria
Inclusion criteria: live singleton pregnancy, being pregnant for 24 to 32 weeks, no symptoms of chorioamniotic, no sign of fetal distress, no vaginal bleeding, consent of mothers to participate in the study. Exclusion criteria: sings of chorioamniotic, disturbed fetal health assessment test, vaginal bleeding, unwillingness of patients to continue participating in the study.
Intervention groups
for randomization, two equal sets of green and blue cards are provided and placed in envelopes (Randomization is done by computer). An envelope will be allocated to each patient. In both green and blue groups, the awaiting treatment is carried out as following: In the first 48 hours of hospitalization, 2 grams of intravenous Ampicillin injection per 6 hours and then for a week, 500-milligram Amoxicillin capsules per 8 hours and 400-milligram Erythromycin pills per 6 hours are prescribed. Also two doses of 12-milligram intramuscular Betamethasone injection within 24 hours is prescribed. Mother's vital signs and fetus health are precisely controlled through daily NST, sonography twice a week and CBC every other day. Additionally for patients who have green sets of cards, during this period of time, one vaginal probiotic capsule made by ZIST TAKHMIR company is prescribed daily for 10 days.2 weeks after delivery, infants and mothers in both groups will be still be followed.
Main outcome variables
Main outcomes: duration of awaiting treatment and pregnancy age at the time of delivery

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20141209020264N3
Registration date: 2018-03-19, 1396/12/28
Registration timing: registered_while_recruiting

Last update: 2018-03-19, 1396/12/28
Update count: 0
Registration date
2018-03-19, 1396/12/28
Registrant information
Name
Seyedeh Azam Pourhoseini
Name of organization / entity
Mashhad University of Medical Science
Country
Iran (Islamic Republic of)
Phone
+98 51 3847 1446
Email address
pourhoseinia@mums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2017-10-23, 1396/08/01
Expected recruitment end date
2019-10-23, 1398/08/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigation of the effects of vaginal probiotic capsules on prolonging the time of membrane rupture up to delivery and on maternal and fetal complications.
Public title
Investigation of the effects of vaginal probiotic capsules on prolonging the time of membrane rupture up to delivery and on maternal and fetal complications.
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
live singleton pregnancy being pregnant for 24 to 32 weeks no symptoms of chorioamniotic no sign of fetal distress no vaginal bleeding consent of mothers to participate in the study
Exclusion criteria:
sings of chorioamniotic disturbed fetal health assessment test vaginal bleeding unwillingness of patients to continue participating in the study
Age
No age limit
Gender
Female
Phase
3
Groups that have been masked
No information
Sample size
Target sample size: 64
Randomization (investigator's opinion)
Randomized
Randomization description
for randomization, two equal sets of green and blue cards are provided and placed in envelopes (Randomization is done by computer). An envelope will be allocated to each patient.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Mashhad University of Medical Sciences
Street address
Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Approval date
2017-09-27, 1396/07/05
Ethics committee reference number
IR.MUMS.REC.1396.194

Health conditions studied

1

Description of health condition studied
prevention of Preterm delivery and maternal and fetal complications
ICD-10 code
060.0
ICD-10 code description
Preterm labour without delivery

Primary outcomes

1

Description
prolonging the time of membrane rupture up to 34 weeks
Timepoint
Precise control of mother's vital signs and fetus health, two times of sonography during a week and CBC every other day
Method of measurement
Fetus health is evaluated through NST.

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: for pregnant women with premature membrane rupture, in the first 48 hours of hospitalization, 2 grams of intravenous Ampicillin injection per 6 hours and then for a week, 500-milligram Amoxicillin capsules per 8 hours and 400-milligram Erythromycin pills per 6 hours are prescribed. Also two doses of 12-milligram intramuscular Betamethasone injection within 24 hours is prescribed. Mother's vital signs and fetus health are precisely controlled through daily NST, sonography twice a week and CBC every other day. Additionally during this period of time, one vaginal probiotic capsule made by ZIST TAKHMIR company is prescribed daily for 10 days.
Category
Treatment - Drugs

2

Description
Control group: for pregnant women with premature membrane rupture, in the first 48 hours of hospitalization, 2 grams of intravenous Ampicillin injection per 6 hours and then for a week, 500-milligram Amoxicillin capsules per 8 hours and 400-milligram Erythromycin pills per 6 hours are prescribed. Also two doses of 12-milligram intramuscular Betamethasone injection within 24 hours is prescribed. Mother's vital signs and fetus health are precisely controlled through daily NST, sonography twice a week and CBC every other day.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Emam Reza hospital
Full name of responsible person
Mahnoush Rohizadeh
Street address
Emam Reza hospital, Emam Reza Sq, Ebne-Sina Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
9137913316
Phone
+98 51 3802 2609
Email
rouhizadehm941@mums.ac.ir

2

Recruitment center
Name of recruitment center
Ghaem hospital
Full name of responsible person
Seyedeh Azam Pourhoseini
Street address
Ghaem hospital, Ahmad Abad Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3801 2477
Email
pourhoseinia@mums.ac.ir

3

Recruitment center
Name of recruitment center
Ommol-Banin hospital
Full name of responsible person
Mahnoush Rohizadeh
Street address
Ommol-Banin hospital, Azadi 16th, Azadi Avenue
City
Mashhad
Province
Razavi Khorasan
Postal code
9144663595
Phone
+98 51 3223 1444
Email
rouhizadehm941@mums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Dr Mohsen Tafaghodi
Street address
Central Building of Mashhad University of Medical Sciences (Ghorshi), Daneshgah 16, Daneshgah street
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3841 2081
Email
ramresearch@mums.ac.ir
Grant name
Grant code / Reference number
951811
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Mashhad University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Seyedeh Azam Pourhoseini
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Ghaem hospital, Ahmad Abad Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3801
Email
pourhoseinia@mums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Seyedeh Azam Pourhoseini
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Ghaem hospital, Ahmad Abad Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3801
Email
pourhoseinia@mums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Mashhad University of Medical Sciences
Full name of responsible person
Seyedeh Azam Pourhoseini
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Ghaem hospital, Ahmad Abad Ave
City
Mashhad
Province
Razavi Khorasan
Postal code
9176699199
Phone
+98 51 3801 2520
Email
pourhoseinia@mums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
All data can be shared after patients are made unidentifiable.
When the data will become available and for how long
Data can be accessible 6 months after results are published.
To whom data/document is available
Data will be available for researchers in universities and other scientific institutes.
Under which criteria data/document could be used
Carrying out analysis on data is permitted.
From where data/document is obtainable
Data can be accessible through sending an email to the corresponding author.
What processes are involved for a request to access data/document
After sending a request email to the corresponding author, data will be sent in 1 month.
Comments
Loading...